Krystal Biotech (KRYS) Competitors

Genmab A/S (NASDAQ:GMAB) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Which has more risk & volatility, GMAB or KRYS?

Genmab A/S has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Is GMAB or KRYS more profitable?

Krystal Biotech has a net margin of 40.85% compared to Genmab A/S's net margin of 37.53%. Genmab A/S's return on equity of 21.03% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
Krystal Biotech	40.85%	15.21%	13.81%

Does the media prefer GMAB or KRYS?

In the previous week, Genmab A/S had 20 more articles in the media than Krystal Biotech. MarketBeat recorded 23 mentions for Genmab A/S and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.21 beat Genmab A/S's score of 0.62 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals believe in GMAB or KRYS?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has higher valuation & earnings, GMAB or KRYS?

Genmab A/S has higher revenue and earnings than Krystal Biotech. Genmab A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	6.90	$1.14B	$1.99	16.86
Krystal Biotech	$290.52M	18.27	$89.16M	$4.92	37.27

Do analysts rate GMAB or KRYS?

Genmab A/S presently has a consensus price target of $40.80, indicating a potential upside of 21.57%. Krystal Biotech has a consensus price target of $209.00, indicating a potential upside of 13.98%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Genmab A/S beats Krystal Biotech on 10 of the 17 factors compared between the two stocks.